AR112471A1 - Antagonistas del receptor del factor liberador de corticotropina - Google Patents
Antagonistas del receptor del factor liberador de corticotropinaInfo
- Publication number
- AR112471A1 AR112471A1 ARP180102314A AR112471A1 AR 112471 A1 AR112471 A1 AR 112471A1 AR P180102314 A ARP180102314 A AR P180102314A AR 112471 A1 AR112471 A1 AR 112471A1
- Authority
- AR
- Argentina
- Prior art keywords
- receptor antagonists
- factor receptor
- releasing factor
- corticotropin releasing
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545393P | 2017-08-14 | 2017-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112471A1 true AR112471A1 (es) | 2019-10-30 |
Family
ID=65362465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102314 AR112471A1 (es) | 2017-08-14 | 2018-08-14 | Antagonistas del receptor del factor liberador de corticotropina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210137935A1 (enExample) |
| EP (1) | EP3630763A4 (enExample) |
| JP (2) | JP7285222B2 (enExample) |
| KR (1) | KR102644781B1 (enExample) |
| CN (1) | CN110997667A (enExample) |
| AR (1) | AR112471A1 (enExample) |
| AU (3) | AU2018318990B2 (enExample) |
| BR (1) | BR112020002966A2 (enExample) |
| CA (1) | CA3064445A1 (enExample) |
| EA (1) | EA202090321A1 (enExample) |
| MX (2) | MX2019015318A (enExample) |
| TW (2) | TWI803504B (enExample) |
| WO (1) | WO2019036472A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL304134B2 (en) | 2014-01-21 | 2025-04-01 | Neurocrine Biosciences Inc | Preparations for the treatment of congenital adrenal hyperplasia |
| CN110997667A (zh) * | 2017-08-14 | 2020-04-10 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| AU2018317398A1 (en) | 2017-08-14 | 2019-11-21 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| CN112423747A (zh) * | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| FI3984523T3 (fi) | 2018-12-07 | 2025-10-21 | Neurocrine Biosciences Inc | Crf1-reseptorin antagonisti, lääkeformulaatioita ja niiden kiinteitä muotoja synnynnäisen lisämunuaisten liikakasvun hoitoon |
| EP3986416A4 (en) * | 2019-07-19 | 2023-06-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| KR20230043222A (ko) | 2020-08-12 | 2023-03-30 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
| EP4203964A1 (en) * | 2020-08-26 | 2023-07-05 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0880523T3 (da) | 1996-02-07 | 2007-03-26 | Neurocrine Biosciences Inc | Pyrazolopyrimidiner som CRF-receptorantagonister |
| DE69926665T2 (de) | 1998-01-28 | 2006-06-08 | Bristol-Myers Squibb Pharma Co. | Azolo-Pyrimidine |
| IL137019A (en) * | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| CA2362816C (en) * | 1999-12-08 | 2007-02-06 | Pharmacia Corporation | Valdecoxib compositions |
| JP2008503444A (ja) * | 2004-02-13 | 2008-02-07 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用 |
| US7612067B2 (en) * | 2005-03-21 | 2009-11-03 | Eli Lilly And Company | Imidazopyridazine compounds |
| WO2008036579A1 (en) * | 2006-09-20 | 2008-03-27 | Eli Lilly And Company | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
| EP2076515B1 (en) * | 2006-09-20 | 2013-07-17 | Eli Lilly And Company | Thiophene pyrazolopyrimidine compounds |
| DK2350079T3 (da) | 2008-10-02 | 2012-12-17 | Lilly Co Eli | Thiazolylpyrazolopyrimidinforbindelser som syntetiske mellemprodukter og dertil relaterede syntetiske fremgangsmåder |
| CN110997667A (zh) * | 2017-08-14 | 2020-04-10 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
-
2018
- 2018-08-14 CN CN201880038596.0A patent/CN110997667A/zh active Pending
- 2018-08-14 AR ARP180102314 patent/AR112471A1/es unknown
- 2018-08-14 WO PCT/US2018/046707 patent/WO2019036472A1/en not_active Ceased
- 2018-08-14 EP EP18846043.0A patent/EP3630763A4/en active Pending
- 2018-08-14 BR BR112020002966-1A patent/BR112020002966A2/pt not_active Application Discontinuation
- 2018-08-14 TW TW107128345A patent/TWI803504B/zh active
- 2018-08-14 KR KR1020207005534A patent/KR102644781B1/ko active Active
- 2018-08-14 EA EA202090321A patent/EA202090321A1/ru unknown
- 2018-08-14 MX MX2019015318A patent/MX2019015318A/es unknown
- 2018-08-14 JP JP2019572820A patent/JP7285222B2/ja active Active
- 2018-08-14 TW TW112117030A patent/TW202400179A/zh unknown
- 2018-08-14 AU AU2018318990A patent/AU2018318990B2/en active Active
- 2018-08-14 CA CA3064445A patent/CA3064445A1/en active Pending
- 2018-08-14 US US16/639,540 patent/US20210137935A1/en not_active Abandoned
-
2019
- 2019-12-16 MX MX2022015858A patent/MX2022015858A/es unknown
-
2023
- 2023-03-20 AU AU2023201703A patent/AU2023201703B2/en active Active
- 2023-05-22 JP JP2023084119A patent/JP7720354B2/ja active Active
-
2024
- 2024-12-16 AU AU2024278470A patent/AU2024278470A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019036472A1 (en) | 2019-02-21 |
| TW202400179A (zh) | 2024-01-01 |
| BR112020002966A2 (pt) | 2020-08-11 |
| AU2023201703B2 (en) | 2024-09-19 |
| CA3064445A1 (en) | 2019-02-21 |
| JP2023116489A (ja) | 2023-08-22 |
| TW201925197A (zh) | 2019-07-01 |
| KR102644781B1 (ko) | 2024-03-06 |
| JP2020530832A (ja) | 2020-10-29 |
| US20210137935A1 (en) | 2021-05-13 |
| MX2019015318A (es) | 2020-07-20 |
| AU2018318990A1 (en) | 2019-11-21 |
| AU2023201703A1 (en) | 2023-04-13 |
| JP7285222B2 (ja) | 2023-06-01 |
| CN110997667A (zh) | 2020-04-10 |
| AU2018318990B2 (en) | 2023-01-05 |
| TWI803504B (zh) | 2023-06-01 |
| KR20200038951A (ko) | 2020-04-14 |
| JP7720354B2 (ja) | 2025-08-07 |
| EP3630763A1 (en) | 2020-04-08 |
| EA202090321A1 (ru) | 2020-09-24 |
| AU2024278470A1 (en) | 2025-01-09 |
| EP3630763A4 (en) | 2021-03-10 |
| MX2022015858A (es) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112471A1 (es) | Antagonistas del receptor del factor liberador de corticotropina | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
| CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
| ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX376433B (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CL2016000495A1 (es) | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. | |
| BR112016001678A2 (pt) | Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| MX378315B (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2015003686A1 (es) | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| MX381819B (es) | Derivados de heterociclico opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias. | |
| CR20210666A (es) | Derivados heterocíclicos condensados | |
| CL2016002482A1 (es) | Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2. | |
| AR099766A1 (es) | Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos | |
| MX2021002444A (es) | Compuestos y metodos para el tratamiento de infecciones fungicas. | |
| ECSP18023544A (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
| MX2021009173A (es) | El monohidrato de clorhidrato de rogaratinib y estados solidos del mismo. | |
| AR105888A1 (es) | Sales de 1-(4-(2-((1-(3,4-difluorofenil)1h-pirazol-3-il)metoxi)etil)piperazin-1-il)etanona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |